共 50 条
- [41] CLINICAL USE OF TOLBUTAMIDE IN DIABETES MELLITUS - A STATEMENT BY THE AMERICAN-DIABETES-ASSOCIATION JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1957, 164 (10): : 1051 - 1052
- [42] Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association CIRCULATION, 2009, 119 (02) : 351 - 357
- [46] Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association DIABETES CARE, 2009, 32 (01) : 187 - 192
- [48] Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (03) : 298 - 304
- [49] GlaxoSmithKline responds to the consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia, 2009, 52 : 986 - 987